Sector News

Stada starts talks with bidders Advent, Cinven

February 14, 2017
Life sciences

Stada Arzneimittel AG Monday said it has begun talks with Cinven Partners LLP and Advent International Corporation, two separate bidders interested in acquiring up to 100% of the German pharmaceutical company.

The company said it received expressions of interest from both Cinven and Advent International and has initiated talks to allow them to discuss strategies and a potential offer price.

Stada said late Sunday it was weighing an approach from Cinven that valued its stock at 3.5 billion euros ($3.7 billion), as well as an approach from a second potential bidder that it didn’t name at the time. The Cinven offer had an indicative price of EUR56 per share, Stada said.

Shares surged 14% higher at the start of trading Monday on the news.

“Both legally non-binding expressions of interest (from the companies), which the Executive Board considered for some time, could offer in different ways attractive opportunities in the interest of the company,” Stada said.

Stada, which makes the cold treatment Grippostad, has been long been considered a possible takeover target for bigger rivals and private-equity firms. It had revenue of EUR2.12 billion in 2015.

By Sarah Sloat

Source: MarketWatch

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach